Verdict No. 3029 · Search date 2026-09-08 · Methodology v1.0
Oral Nigella sativa seed oil as adjunctive therapy,
does it really help with Improved DAS28 disease activity and joint symptoms in rheumatoid arthritis?
30-Second Summary
C
Evidence Grade C · 50 · Safety caution
Biomarker reports on hs-CRP, TNF, IL-10, and oxidative stress are not independent DAS28 replications.
Composition varies by product and extraction method. People who are pregnant or breastfeeding, children, those with liver or kidney disease, and anyone using glucose-, blood-pressure-, anticoagulant-, antiseizure-, or immune-modifying medicines should seek clinical advice. Small trials cannot exclude rare or long-term harms.
What the
research showsGrade C with 50 points. Small trials in women reported lower DAS28, but one used a fixed placebo-then-oil sequence and the parallel cohort has conflicting completion denominators of 39, 42, and 43 across reports.
research showsGrade C with 50 points. Small trials in women reported lower DAS28, but one used a fixed placebo-then-oil sequence and the parallel cohort has conflicting completion denominators of 39, 42, and 43 across reports.
What the
ads claimReplacement of antirheumatic drugs, prevention of structural damage, and cure were not tested.
ads claimReplacement of antirheumatic drugs, prevention of structural damage, and cure were not tested.
Useful facts when choosing a product
- This verdict applies only to the exact plant part, formulation, route, dose, population, endpoint, and comparator shown above.
- Seed powder, fixed oil, aqueous extract, ethanolic topical preparation, purified thymoquinone, and combinations are not interchangeable.
- Composition varies by product and extraction method. People who are pregnant or breastfeeding, children, those with liver or kidney disease, and anyone using glucose-, blood-pressure-, anticoagulant-, antiseizure-, or immune-modifying medicines should seek clinical advice. Small trials cannot exclude rare or long-term harms.
Chamgap Semantic Classification Code
Permanent code issued
S.nigella-sativa.oral.rheumatoid-arthritis-disease-activity.improve.addonSupplements and nutraceuticals > Nigella sativa > Oral > Rheumatoid-arthritis disease activity > Improvement claim > Add-on to common antirheumatic care
Issued for clinical DAS28 activity; biomarker papers from the same cohort are not independent replications. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Nigella sativa |
| Source or part used | Nigella sativa L. seed |
| Formulation or processing | Fixed seed-oil capsules; manufacturer-prepared product |
| Route | Oral |
| Dose | 500 mg twice daily, 1 g/day total |
| Duration | One to two months; no long-term follow-up |
| Population | Women with rheumatoid arthritis continuing stable antirheumatic medication |
| Effect or condition | Improved disease activity and joint symptoms |
| Primary endpoint | DAS28 |
| Comparator | Starch placebo added to common antirheumatic therapy |
| Duplicate-detection key | nigella-sativa|seed-oil-capsule|oral|women-ra-stable-dmards|das28-improvement|1-2-months |
Gap Measurement · Verdict 3029 · C 50
What the research actually shows
Seed oil was added while background DMARD and steroid treatment remained stable.
Why this is classified as C (50)
A positive clinical-scale contrast is offset by small trials, inconsistent denominators, masking limitations, and company involvement, yielding C with 50 points.
Counterpoint. Uncertainty does not prove no effect, but a signal from one formulation cannot validate another formulation or claim.
Rejudgment record. Independent Codex cross-check — One page, one route, one population, one claim, one principal comparator
Scoring profile behind this grade
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Anti-inflammatory and antioxidant effects of Nigella sativa oil in rheumatoid arthritis | The cited controlled design and its allocation or masking limitations were independently checked. | 40 | Funding, product support, and employee authorship were assessed separately; unverified items were not counted as strengths. | The principal endpoint is defined in the exact facets; secondary outcomes remain separate. | The verified quantitative result is reported in the English reader answer and rationale without inventing missing confidence intervals. | No randomized period order |
| Immunomodulatory effect of Nigella sativa oil on T lymphocytes in rheumatoid arthritis | The cited controlled design and its allocation or masking limitations were independently checked. | 43 | Funding, product support, and employee authorship were assessed separately; unverified items were not counted as strengths. | The principal endpoint is defined in the exact facets; secondary outcomes remain separate. | The verified quantitative result is reported in the English reader answer and rationale without inventing missing confidence intervals. | Main parallel cohort; secondary papers not independent |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-09-08).
Gheita TA, Kenawy SA. Nigella sativa oil in rheumatoid arthritis. Phytother Res. 2012. PMID: 22162258. DOI: 10.1002/ptr.3679.
checkedKheirouri S et al. Nigella sativa oil and rheumatoid arthritis disease activity. Immunol Invest. 2016. PMID: 27100726. DOI: 10.3109/08820139.2016.1153649.
checkedResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Nigella Seed Oil for Rheumatoid Arthritis—A DAS28 Signal With Small Trials and Denominator Inconsistencies — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/oral-nigella-sativa-oil-adjunct-rheumatoid-arthritis-activity/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.